Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Kalaris Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Kalaris Therapeutics's enterprise value was -$48.27M on Nov 11, 2026, against $116.63M a year earlier. Over the last 5 years it ranged from -$135.83M to $541.65M, with a median of $5.65M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | -$48.27M | -130.6% |
| 2025 | Dec 31, 2025 | $157.77M | – |
| 2024 | Dec 31, 2024 | -$73.42M | – |
| 2023 | Dec 29, 2023 | -$135.83M | -164.3% |
| 2022 | Dec 30, 2022 | $211.12M | -61.0% |
| 2021 | Dec 31, 2021 | $541.65M | -72.8% |
| 2020 | Dec 31, 2020 | $1.99B | – |
See a number that looks wrong?